HMT would like to personally invite you to our inaugural Webinar: Isotope Analyses: Modeling the Ever-Changing Metabolic Landscape.

Human Metabolome Technologies, Inc. (hereinafter referred to as
HMT, Head office: Tsuruoka City, Yamagata Prefecture, Chief Executive Officer: Ryuji Kanno,) and Pharmalegacy Laboratories (Shanghai) Co., Ltd.（hereinafter referred to as PLS, Chief Executive Officer: Jeff Duan）announced a strategic partnership. The scope of partnership includes information sharing and co-operation in sales and marketing activities in order to help each other’s growth in the overseas market.

China’s presence in bioscience research and development has been dramatically increasing over the past few years. Against this background, HMT has started to provide metabolomics service in China to support academic and industry clients using our advanced technology and know-how.

PLS is a leading specialty pharmacology contract research organization located in Shanghai Zhangjiang High-Tech Park, China, where many international and Chinese pharmaceutical companies have R&D laboratories. It is equipped with a world-class facility including AAALAC, working for international pharmaceutical industrial standards.

Boston, MA – On January 24, 2018, Human Metabolome Technologies, Inc. (hereinafter referred to as HMT, Head office: Tsuruoka City, Yamagata Prefecture, President: Ryuji Kanno,) have announced that a biomarker for the diagnosis of Major Depression Disorder (MDD), which is being developed collaboratively with the Medical Corporation Association Gyo-ki kai, Kawamura general clinic (Tokyo, Japan, Representative: Noriyuki Kawamura, MD), has been published in Psychiatry and Clinical Neurosciences.

Boston, MA – On October 19, 2017, Human Metabolome Technologies, Inc. (hereinafter referred to as HMT, Head office: Tsuruoka City, Yamagata Prefecture, President: Ryuji Kanno,) and Toyobo Co., Ltd. (Head Office: Osaka Prefecture Osaka City, Representative Director: President: Seiji Narahara, Toyobo) have announced that they have collaboratively established mass-production technology for the enzyme Ethanolamine-phosphate phospho-lyase used for measurement of a depression-related biomarker. In the future, Toyobo will provide this enzyme to HMT and HMT will manufacture and sell a research reagent kit.

1. Background
   The number of patients with depression is 322 million people worldwide*1 and the domestic economic loss amount is considered to be about 3 trillion yen*2 per year in Japan. Diagnosis of depression is currently focused mainly on interviews by specialists, but the background and
   symptoms of onset are diversified and therefore highly accuracy alternative diagnosis is required. HMT has revealed that the concentration of plasma Ethanolamine Phosphate (PEA) is reduced relating to the depressive state and its usefulness as a biomarker to assess Major Depressive Disorder (MDD) is being studied.
   *1 … Study by WHO in 2015
   *2 … 2011 school corporation Keio University “Fiscal 2010 Ministry of Health, Labor and Welfare Disability Welfare General Promotion Project subsidy” Mental illness Estimation of
   Social Cost of “Business Performance Report” 
2. Currently
   The measurement of PEA concentration in the plasma for clinical diagnosis requires specific analytical methods with selectivity, sensitivity, and throughput. Therefore, HMT is developing reagent kits based on an enzymatic assay for PEA together with its analytical method. By using this kit, it will be possible for many medical institutions and laboratories to quickly and easily measure PEA concentrations. Toyobo, which has a proven practice in the manufacture of diagnostic enzymes, has been collaborating with HMT for the development of this kit using their
   established mass-production technologies. Toyobo will begin to provide this enzyme to HMT starting November 2017.
3. Future plans
   Toyobo will provide Ethanolamine-phosphate phospho-lyase as a component of the PEA reagent kit and support the development of a next-generation in vitro diagnostic system for depression. HMT will proceed with the establishment of the manufacturing and sales of a PEA reagent kit, improving the assessment of MDD and provide these kits to a wide range of clinical research institutes in 2018.

Boston, MA – October 21, 2016: Human Metabolome Technologies (HMT) has been awarded a contract to work with the National Institute on Aging (NIA) on a study looking at the mechanisms associated with Alzheimer’s disease (AD). It is hoped that prevention and treatment of AD can be accelerated by combining clinical, genetic, epidemiologic, and imaging research with comprehensive metabolic phenotyping of human brain tissue.

The project is led by Madhav Thambisetty, M.D., Ph.D., Clinical Investigator at the NIA and Chief of the Unit of Clinical and Translational Neuroscience in the Institute’s Laboratory of Behavioral Neuroscience. The unit’s overall goals are to enhance understanding of disease mechanisms operating in AD, as well as, to identify novel biomarkers that might be predictive of disease
before the onset of symptoms.

In this current initiative, HMT will provide high-resolution metabolomic profiling of human brain tissue samples provided by the NIA, using unique capillary electrophoresis mass spectrometry platforms to measure absolute and relative levels of metabolites associated with many pathways critical in the pathogenesis of AD.

Boston, Mass. – October 1, 2015 – Human Metabolome Technologies Inc. (HMT) has agreed to a licensing agreement with Sysmex Corporation (TSE; 6869, Hisashi Ietsugu- Chairman & CEO; Kobe-City, Hyogo Pref. JAPAN) regarding HMT’s patent for a blood
biomarker for Depressive Disorder. HMT has researched and developed a blood biomarker (Phosphoethanolamine – PEA) for Depressive Disorder in cooperation with National Center of Neurology and Psychiatry (NCNP) and GYOKIKAI Medical Corporation (Director Noriyuki Kawamura MD; Tokyo, JAPAN). HMT has registered patents in Japan, USA, and China covering this discovery. HMT and Sysmex have signed a contract for the
collaborative research and development of a test kit which will measure the concentration of the patented MDD biomarker (PEA) using an enzymatic method developed and issued by HMT in August 2013. Under the cooperative research and development licensing agreement, HMT has given approval to Sysmex to utilize our patent license of the specified MDD biomarker PEA for clinical development.

Boston, Mass. – July 7, 2014 – Human Metabolome Technologies, Inc. (HMT), the leading developer of capillary electrophoresis mass spectrometry (CE-MS) based metabolomics, has been recognized by the National Cancer Center’s Office of Science and Technology Resources (OSTR) as a preferred vendor of metabolomic services. Under this program, new technology costs are subsidized by the OSTR in an effort to advance cancer research for NCI’s Center for Cancer Research (CCR) investigators.

Alexander Buko, Ph.D., Vice President of HMT said, “We are excited by this new partnership. The NCI has acknowledged that we have a unique technology that researchers can benefit from”.
HMT is making available its landmark CARCINOSCOPE™ analysis package. “CARCINOSCOPE is the only quantitative metabolite profiling option available to researchers and having the NCI recognize the impact of this technology is a testament to the quality of data we provide,” said Dr. Buko. “Whether you are directly targeting metabolic pathways or commonly mutated signaling pathways, the cancer cells’ metabolism will be altered. Integrating metabolic studies with traditional genetic and proteomic studies is the only way to get a full picture of cancer.
CARCINOSCOPE™ was specifically designed for those affected metabolic pathways.”